Evidence map›Paper›PMID 40177087›Full record

ArticleFrontiers in public health2025

Factors affecting viral suppression or rebound in people living with HIV and receiving antiretroviral therapy in Ghana.

Anthony T Boateng, James O Aboagye, Helena Lamptey, Christopher Z-Y Abana, Araba Abaidoo-Myles, Darius N K Quansah, Seth Agyemang, Yaw Awuku-Larbi, Gloria Ansa, Joseph Oliver-Commey and 4 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anthony T BoatengDepartment of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana.
James O AboagyeDepartment of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana.
Helena LampteyDepartment of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana.
Christopher Z-Y AbanaDepartment of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana.
Araba Abaidoo-MylesDepartment of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana.
Darius N K QuansahDepartment of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana.
Seth AgyemangWest African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Accra, Ghana.
Yaw Awuku-LarbiDepartment of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana.
Gloria AnsaPublic Health Unit, University of Ghana Hospital, Accra, Ghana.
Joseph Oliver-CommeyLEKMA Hospital, Accra, Ghana.
Vincent GanuDepartment of Medicine, University of Ghana School of Medicine, College of Health Sciences, University of Ghana, Accra, Ghana.
George B KyeiDepartment of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana.
Peter PuplampuDepartment of Medicine, University of Ghana School of Medicine, College of Health Sciences, University of Ghana, Accra, Ghana.
Evelyn Y BonneyDepartment of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana.

Funding

Training and Research on Arboviruses and Zoonoses In Nigeria and Sierra Leone (TRAIN)D43TW012246 · FIC · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Nikos Vasilakis, Scott C Weaver · 2022 to 2026
$1.2M
FIC NIH HHS D43 TW012246
6 · The paper itself

Abstract

Introduction: Regular viral load (VL) testing for people living with HIV (PLWH) is key to attaining the Joint United Nations Program on HIV/AIDS (UNAIDS) Fast-Track 95-95-95 target to end the HIV epidemic by 2030. However, VL testing remains sporadic in routine HIV care in the majority of resource-limited settings, including Ghana, except when provided through research initiatives. In this study, we measured VL among PLWH in Ghana at regular intervals and investigated factors affecting viral suppression (VS) and rebound. Methods: We analyzed data from a hospital-based cohort enrolled in our HIV cure research. Participants were recruited from three hospitals in the Greater Accra region of Ghana. Demographic characteristics were obtained from participants' folders, while CD4 Results: The study participants were predominantly women (68%) with a median age of 45 years (IQR: 21-76 years). A total of 52% of participants had been on antiretroviral therapy (ART) for more than 6 years, and 74% were following dolutegravir-based regimens. At baseline, 74% of participants had a VL of <50 copies/mL, which increased to 88% at 18 months, with 80% having a CD4 Conclusion: A key feature of our study was measuring VL at three time points over 2 years, which may explain the high VS levels observed. Viral rebound was linked to low education levels, highlighting the need for targeted education for PLWH with junior high school (JHS) education or less. Regular VL monitoring and the implementation of measures to prevent viral rebound, particularly among PLWH with lower education levels, will help Ghana move closer to attaining the third "95" of the UNAIDS 95-95-95 target by 2030.

Indexed as

Anti-HIV AgentsAnti-Retroviral AgentsHIV InfectionsViral LoadAdultAgedCD4 Lymphocyte CountCohort StudiesDolutegravirFemaleGhanaHeterocyclic Compounds, 3-RingHumansMaleMiddle AgedOxazinesAnti-HIV AgentsAnti-Retroviral AgentsDolutegravirHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesARTHIVviral loadviral reboundviral suppression

Identifiers

PMID40177087
PMCPMC11961867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.